Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:11:41 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:XAIR from 2023-05-04 to 2024-05-03 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 07:00U:XAIRNews ReleaseBeyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
2024-03-20 09:00U:XAIRNews ReleaseBeyond Air(TM) Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
2024-02-12 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Reports Financial Results ‚  for Third Quarter of Fiscal Year 2024
2024-01-18 08:00U:XAIRNews ReleaseBeyond Air ‚ ® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
2023-12-27 07:30U:XAIRNews ReleaseBeyond Cancer ¢ „ ¢ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
2023-11-15 16:05U:XAIRNews ReleaseBeyond Air ‚ ® To Participate in the 35th Annual Piper Sandler Healthcare Conference
2023-11-13 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Reports Financial Results for Second Quarter of Fiscal Year 2024
2023-11-03 12:00U:XAIRNews ReleaseBeyond Cancer ¢ „ ¢ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
2023-10-19 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
2023-10-17 16:05U:XAIRNews ReleaseBeyond Air ‚ ® To Participate in the Truist Securities BioPharma Symposium
2023-10-17 07:30U:XAIRNews ReleaseBeyond Cancer ¢ „ ¢ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice
2023-10-16 07:30U:XAIRNews ReleaseBeyond Cancer ¢ „ ¢ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-10-16 07:00U:XAIRNews ReleaseBeyond Air ‚ ® Receives Innovative Technology Contract from Vizient ‚  for LungFit ‚ ®PH
2023-10-04 07:30U:XAIRNews ReleaseBeyond Cancer ¢ „ ¢ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-10-02 16:05U:XAIRNews ReleaseBeyond Air ‚ ® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference
2023-09-27 09:00U:XAIRNews ReleaseBeyond Cancer ¢ „ ¢ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
2023-09-18 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder
2023-09-07 07:30U:XAIRNews ReleaseBeyond Air ‚ ® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region
2023-09-06 07:00U:XAIRNews ReleaseBeyond Air ‚ ® To Participate in the 2023 Cantor Global Healthcare Conference
2023-08-10 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Reports Financial Results ‚  for First Quarter of Fiscal Year 2024
2023-08-07 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)
2023-08-01 16:05U:XAIRNews ReleaseBeyond Air ‚ ® To Participate in BTIG ¢ € ™s 2023 Virtual Biotechnology Conference
2023-07-24 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
2023-06-22 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023
2023-06-15 16:10U:XAIRNews ReleaseBeyond Air ‚ ® Secures up to $40 Million Debt Financing
2023-06-15 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
2023-05-16 16:05U:XAIRNews ReleaseBeyond Air ‚ ® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast